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Charge-switchable polymeric complex for  
glucose-responsive insulin delivery in mice and pigs
Jinqiang Wang1,2,3*, Jicheng Yu3*, Yuqi Zhang3, Xudong Zhang1,2, Anna R. Kahkoska4, 
Guojun Chen1,2, Zejun Wang1,2, Wujin Sun1,5, Lulu Cai1,2,6, Zhaowei Chen3, Chenggen Qian7, 
Qundong Shen7, Ali Khademhosseini1,2,5,8,9, John B. Buse4, Zhen Gu1,2,3,5,10†
Glucose-responsive insulin delivery systems with robust responsiveness that has been validated in animal models, 
especially in large animal models, remain elusive. Here, we exploit a new strategy to form a micro-sized complex 
between a charge-switchable polymer with a glucose-sensing moiety and insulin driven by electrostatic interac-
tion. Both high insulin loading efficiency (95%) and loading capacity (49%) can be achieved. In the presence of a 
hyperglycemic state, the glucose-responsive phenylboronic acid (PBA) binds glucose instantly and converts the 
charge of the polymeric moiety from positive to negative, thereby enabling the release of insulin from the complex. 
Adjusting the ratio of the positively charged group to PBA achieves inhibited insulin release from the complex 
under normoglycemic conditions and promoted release under hyperglycemic conditions. Through chemically 
induced type 1 diabetic mouse and swine models, in vivo hyperglycemia-triggered insulin release with fast response 
is demonstrated after the complex is administrated by either subcutaneous injection or transdermal microneedle 
array patch.
INTRODUCTION
Diabetes mellitus and related secondary complications (1) affect 
and threaten the lives of 422 million people worldwide (2, 3). Ideal 
diabetes management relies on the tight regulation of blood glucose 
levels (BGLs) to prevent long-term complications and optimize the 
quality of life. The conventional method for controlling BGLs involves 
the repeated subcutaneous injections of insulin based on glucose 
monitoring as well as expected carbohydrate intake and activity. 
Unfortunately, self-injection is fraught with challenges relating to 
adherence and dose selection, limiting the efficacy of glucose regu-
lation and leading to a high risk of hypoglycemia, which can be fatal 
(1). Thus, various insulin delivery methods have been developed to 
address these problems and make insulin administration easier (4). 
Examples include insulin delivery systems that work in response to 
external stimuli like pH (5, 6), temperature (7), ultrasonic radiation 
(8–10), mechanical force (11), ionic strength (12), magnetic field 
(13), and light (14). However, there remain challenges for these systems 
to quickly control the hyperglycemic state and reduce the risk of 
hypoglycemia upon insulin delivery.
To this end, substantial efforts have been devoted to the develop-
ment of self-regulated, glucose-responsive insulin delivery systems 
(15, 16). Most of these systems have relied on the specific interaction 
of glucose with glucose oxidase (GOx) (17–21), glucose-binding 
protein (22–25), and phenylboronic acid (PBA) (26–34). For example, 
GOx-catalyzed oxidation of glucose can generate acidic (35–38), 
hypoxic (39, 40), and/or oxidative conditions (40–42), leading to 
the degradation, swelling, or dissolution of the matrices and subse-
quent release of preloaded insulin. Nevertheless, these systems still 
face several challenges, including slow response rate, low insulin 
loading efficiency, poor biocompatibility, and complicated manu-
facturing processes (16).
Here, we describe a new strategy for constructing a glucose- 
responsive insulin delivery formulation with fast response both in 
vitro and in vivo based on a glucose-triggered charge switch of a 
cationic polymer. As shown in Fig. 1A, a positively charged polymer 
is incorporated with pendant amino groups and PBA groups. In 
phosphate-buffered saline at pH 7.4 (PBS 7.4), this polymer is posi-
tively charged and is able to form a stable micro-sized suspension 
with a high insulin loading efficiency of 95% and a high loading 
capacity of 49% (Fig. 1B and fig. S1, A to D). In the presence of 
glucose, the binding of glucose to PBA in polymers leads to a decrease 
of positive charge density, thereby weakening the polymer’s electro-
static attraction to insulin. Under hyperglycemic conditions, the 
positive charge of the polymer can be reversed, facilitating insulin 
release with fast response (Fig. 1, A and C). Meanwhile, this charge 
reversal is inhibited with the return to normoglycemia, thereby 
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(43, 44). The chemical structures were characterized by 1H nuclear 
magnetic resonance (NMR) (fig. S2, A to C), while the molecular weight 
of poly(Boc-EDAA) was 8.7 × 103 g/mol with a polydispersity index of 
2. 4-Carboxy-3-fluorophenylboronic acid (FPBA), with a suitable pKa
(where Ka is the acid dissociation constant) of 7.2 because of the intro-
duction of fluorine (34), was activated as N-hydroxysuccinimide (NHS) 
ester and used to prepare poly(EDAA0.4-FPBA0.6) and poly(EDAA0.7- 
FPBA0.3) (fig. S2, D to F). As a comparison, 4-carboxyphenylboronic
acid was also activated by NHS (27) (fig. S2G) and used to modify
poly(EDAA) to produce poly(EDAA0.4-PBA0.6) (fig. S2H).
Preparation of insulin complex
Next, complexes were prepared from insulin and poly(EDAA0.4-FPBA0.6) 
with various ratios. Both insulin and poly(EDAA0.4-FPBA0.6) were 
dissolved in slightly acidic water and then mixed. After adjusting the 
pH to 7.4, a white suspension was obtained (Fig. 1C), indicating the 
formation of polymer-insulin complex. The complex precipitation 
was highly stable, suggesting a strong interaction between insulin 
and polymer. In addition, the water insolubility of poly(EDAA0.4- 
FPBA0.6) is proposed to be vital for stabilizing the complex formed 
between polymer and insulin (45).
In vitro glucose-responsive performance
The ability of polymers binding to glucose was evaluated in PBS 7.4 with 
varying clinically relevant glucose concentrations of 100, 200, and 
400 mg/dl. Polymer-insulin complexes composed of an equal weight 
of insulin and polymer, namely, poly(EDAA0.4-FPBA0.6)–complexed 
insulin (designated as F-insulin), poly(EDAA0.4-PBA0.6)– complexed 
insulin (designated as B-insulin), and poly(EDAA)–complexed insulin 
(designated as N-insulin), were prepared. After the addition of glucose 
to F-insulin solution containing insulin [1 mg (or 28.8 U)/ml], the 
concentration of glucose decreased by around 10, 15, and 35 mg/dl 
for glucose solutions of 100, 200, and 400 mg/dl, respectively, within 
10 min (Fig. 2A and fig. S1E). Unexpectedly, further binding of glu-
cose to F-insulin was observed in glucose solution (400 mg/dl) such 
that a total decrease of 50 mg/dl of the glucose concentration within 
2 hours was observed, indicating that approximately 90% of FPBA 
moiety was bound to glucose, probably ascribed to the enhanced 
diol-capturing ability arising from adjacent amino groups (46, 47). 
As a comparison, no glucose binding or negligible binding was observed 
for the solution of B-insulin and N-insulin (Fig. 2, B and C) (48).
To determine whether glucose binding could lead to the reduction 
of positive charge density on polymers, polymeric nanoparticles 
were prepared by dripping the concentrated acidic aqueous solution 
of poly(EDAA0.4-FPBA0.6) or poly(EDAA0.4-PBA0.6) to PBS 7.4. 
Both polymers formed stable spherical nanoparticles as measured by 
the dynamic laser scattering (DLS) and transmission electron 
microscopy (TEM) (Fig. 2, D and E). Meanwhile, the original  poten-
tial of poly(EDAA0.4-FPBA0.6) nanoparticles was +40 mV in the 
absence of glucose (Fig. 2F), which gradually decreased to +22 mV 
Fig. 1. Schematic of glucose-responsive charge-reversal polymers for insulin delivery. (A) Mechanism of glucose-sensitive charge reversal and enhanced insulin 
release from complex under a hyperglycemic state. The complex was prepared from a positively charged polymer and the negatively charged insulin via electrostatic 
interaction. (B) Representative fluorescence images of complex formed from poly(EDAAx-FPBAy) [green, fluorescein isothiocyanate (FITC)–labeled] and insulin (red, 
rhodamine B–labeled). Scale bar, 500 m. (C) Representative images of the complex before (left) and after (right) treatment of glucose (400 mg/dl) for 3 hours at 37°C.
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in glucose solution of 100 mg/dl and further decreased to +8 mV 
in glucose solution of 400 mg/dl. Because poly(EDAA0.4- FPBA0.6) 
precipitated within 5 min after the glucose concentration in-
creased to 400 mg/dl, we were unable to measure the  potential of 
poly(EDAA0.4-FPBA0.6)–glucose complex directly. However, based 
on both the high efficiency of glucose binding (~90% FPBA bound 
to glucose) and the pKa of FPBA (~6.4) in glucose solution (400 mg/dl) 
(34), about 90% of FPBA should carry a negative charge at pH 7.4, 
therefore making poly(EDAA0.4-FPBA0.6) negatively charged.
Next, the insulin release from the complexes upon glucose con-
centration variation was assessed. The insulin release kinetics can 
be tuned by varying the weight ratios of poly(EDAA0.4-FPBA0.6) to 
insulin (fig. S3, A to C), with F-insulin showing the most robust 
insulin release kinetics, which was further validated by measuring 
the fluorescence intensity of rhodamine B–labeled insulin (RhB- 
insulin) released from F-insulin (Fig. 3A and fig. S1F). In contrast, 
B-insulin or poly(EDAA0.7-FPBA0.3)–insulin complex exhibited a
relatively slow insulin release rate (Fig. 3B and fig. S3D). Moreover,
the insulin release rate was steadily increased in response to glucose 
concentration variation (from 100 to 400 mg/dl), achieving a maximum 
of fourfold enhancement (Fig. 3C). This fast insulin release kinetics
upon glucose concentration variation has the potential to regulate
BGLs in real time effectively. In addition, F-insulin also achieved
pulsatile insulin release for several cycles by alternating glucose
concentrations between 100 and 400 mg/dl (Fig. 3D). Meanwhile,
the far-ultraviolet circular dichroism spectra results suggested that
the released insulin retained -helical secondary structure and bio-
activity (fig. S3E).
In vivo evaluation of the complex in diabetic mice
The in vivo therapeutic efficacy of complex was evaluated in type 1 
diabetic mouse model induced by streptozotocin (STZ). The diabetic 
mice were assigned to be treated with either F-insulin, B-insulin, 
and native insulin at a dose of 80 U/kg or PBS. The BGLs of all treated 
groups decreased to below 200 mg/dl, indicating the retention of 
Fig. 2. The glucose binding and charge-switch study. (A to C) Glucose concentration–dependent glucose-binding ability of F-insulin (A), B-insulin (B), and N-insulin (C). 
The complexes were incubated in glucose solutions (100, 200, or 400 mg/dl). Data points are means ± SD (n = 3). (D and E) Hydrodynamic size distribution determined by 
DLS and representative TEM images of nanoparticles prepared from poly(EDAA0.4-FPBA0.6) (D) and poly(EDAA0.4-PBA0.6) (E). (F) Glucose concentration–dependent  
potentials of nanoparticles prepared from poly(EDAA0.4-FPBA0.6) and poly(EDAA0.4-PBA0.6). Data points are means ± SD (n = 3). Statistical significance was calculated using 
Student’s t test. ***P < 0.001. NS, not significant.
Fig. 3. Glucose- and structure-dependent insulin release. (A and B) Glucose-dependent 
insulin release from F-insulin (A) and B-insulin (B) over time. Insulin was labeled 
with rhodamine B. The glucose concentrations were set to 0, 100, 200, and 400 mg/dl. 
Data points are means ± SD (n = 3). a.u., arbitrary units. (C) Cumulative insulin 
release profile of F-insulin. The complex was incubated in each solution for 10 min. 
Data points are means ± SD (n = 3). (D) Pulsatile insulin release from F-insulin 
by alternating the glucose concentration. The complex was incubated in each 
solution for 2 min. Data points are means ± SD (n = 3).
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activity of complexed insulin (Fig. 4A). Moreover, F-insulin was 
shown to maintain BGLs within the normal range (<200 mg/dl) for 
more than 8 hours, much longer than native insulin and B-insulin 
(Fig. 4B). The live imaging results further confirmed the prolonged 
retention of subcutaneously injected F-insulin as compared with 
native insulin (Fig. 4C).
Next, the superior release rate of insulin under hyperglycemic 
conditions from the F-insulin complex was evaluated. A spike of 
plasma insulin level of approximately 7500 U/ml was observed at 
~30 min after injection of F-insulin (fig. S4A), consistent with the 
rapid down-regulation of BGLs. The plasma insulin level quickly 
decreased to approximately 750 U/ml at 1.5 hours and further 
Fig. 4. In vivo evaluation of insulin complex for type 1 diabetic mice treatment. (A) BGLs of type 1 diabetic mice treated with subcutaneously injected native insulin, 
F-insulin, or B-insulin. PBS was used as a control. The insulin-equivalent dose was 80 U/kg. Data points are means ± SD (n = 5). Statistical significance between groups
treated with F-insulin and native insulin was calculated. (B) Normoglycemic time of mice treated with subcutaneously injected F-insulin, B-insulin, and native insulin.
Statistical significance was calculated. Data points are means ± SD (n = 5). (C) Live imaging of subcutaneously injected F-insulin and native insulin labeled with sulfo-Cy5.
(D) IPGTT in diabetic mice at 3 hours after treatment of F-insulin or native insulin. Glucose dose was set to 1.5 g/kg. Healthy mice were used as control. Data points are 
means ± SD (n = 5). Statistical significance between F-insulin– and native insulin–treated groups was calculated. (E) Responsiveness to IPGTT in terms of the area under 
the curve (AUC) in 150 min, with the baseline set at the 0-min blood glucose reading. Data points are means ± SD (n = 5). Statistical significance between groups was
calculated. (F) In vivo glucose-responsive insulin release triggered by intraperitoneal glucose injection at 4 hours after treatment of F-insulin at a dose of 80 U/kg. Glucose 
dose was set to 2 g/kg. Data points are means ± SD (n = 4 to 5). Statistical significance between the plasma insulin levels at various time points after glucose challenge and 
that at 0 min was calculated. Inset: Representative image of the resultant light yellow solution associated with enzyme-linked immunosorbent assay (ELISA) measure-
ment. Plasma collected at 0, 10, 20, 30, 40, 60, 90, and 120 min after treatment of F-insulin was added to each well one by one from left to right. 5,5′-Tetramethylbenzidine 
(TMB) was used as the substrate of horseradish peroxidase, and the addition of sulfuric acid (0.6 N) turned the blue product of TMB to light yellow. (G) Representative 
scanning electron microscopy image of the MN arrays. Inset: Representative fluorescence image of the MNs loaded with F-insulin. Insulin was labeled with rhodamine 
B. Scale bar, 300 m. (H) BGLs of type 1 diabetic mice treated with MN array patches loaded with insulin (MN-insulin) or F-insulin (MN–F-insulin) (2 mg of insulin per patch). 
Blank MN loaded with PBS was used as a negative control. One patch was applied to one mouse. Statistical significance between the groups treated with MN-insulin and 
MN–F-insulin was calculated. Data points are means ± SD (n = 5). (I) In vivo glucose-responsive insulin release triggered by intraperitoneal glucose injection at 3 hours after 
treatment of MN array patch load with F-insulin. Each mouse was treated with one patch containing 2 mg of insulin encapsulated in the complex. Glucose was given at 2 g/kg. 
Data points are means ± SD. (n = 4). Statistical significance between the plasma insulin levels at various time points after glucose challenge and that at 0 min was calculated. All 
the statistical analyses were performed by one-way analysis of variance (ANOVA) with a Tukey post hoc test or Student’s t test. *P < 0.05, **P < 0.01, and ***P < 0.001.
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decreased to 22 U/ml at 4 hours after treatment, which was essen-
tial for maintaining normoglycemia while avoiding hypoglycemia. 
By comparison, the plasma insulin level of mice treated with B- 
insulin showed a flat peak of insulin level at 30 min after injection 
(fig. S4A), which was mainly due to the burst release of loosely 
adsorbed insulin. However, the fast elimination of insulin from the 
circulation (49) and slow insulin release from B-insulin failed to 
maintain a therapeutically effective blood insulin level.
Intraperitoneal glucose tolerance tests (IPGTTs) associated with 
in vivo glucose response were further performed 3 hours after treat-
ment with F-insulin. Blood glucose peaks were observed for all groups 
after intraperitoneal glucose injection (Fig. 4, D and E), while only 
the healthy mice and F-insulin–treated diabetic mice reestablished 
normoglycemia in a brief period. For mice treated with F-insulin, 
associated with the increase in blood glucose (Fig. 4F), a remarkable 
spike of plasma insulin (from 30 to 250 U/ml) (Fig. 4F) was observed, 
and then it gradually decreased to 39 U/ml. In contrast, mice treated 
with insulin glargine, commercialized long-acting insulin, showed no 
change in plasma insulin level during IPGTT (fig. S4B). This fast in vivo 
glucose- responsive insulin release kinetics is essential for maintaining 
normoglycemia when facing glucose challenges. Furthermore, the 
poly(EDAA0.4-FPBA0.6) used for F-insulin was mainly eliminated from 
the body through the liver (fig. S4C).
To further demonstrate the potential of glucose-sensitive F- insulin 
in regulating glycemia over time, insulin complexes were sub-
cutaneously co-injected with in situ–formed absorbable gel [Pluronic 
F-127 (PF-127)] (50). Similar experimental groups were set but with 
an increased insulin dose (300 U/kg). Compared to other insulin for-
mulations, only F-insulin was found to be able to regulate blood glu-
cose within a normal range for more than 30 hours (fig. S4D). Upon 
IPGTT, F-insulin loaded in PF-127 could regulate glucose back to 
normal range rapidly, which was comparable to that of sub cutaneously 
injected F-insulin (fig. S4E). The diabetic mice were further treated 
continuously for 2 weeks to evaluate the longer-term glucose- 
regulating efficacy. The diabetic mice receiving F-insulin and insulin 
glargine were able to maintain their BGLs within the normal range 
with a longer duration compared to those treated with native insulin 
(fig. S4F). During the whole treatment, negligible antibodies including 
immunoglobulin E (IgE), immunoglobulin M (IgM), and immuno-
globulin G (IgG) were generated against the subcutaneously injected 
materials and insulin (fig. S5A). Moreover, negligible changes were 
observed in blood cell counts, albumin (ALB), aspartate aminotrans-
ferase (AST), and blood urea nitrogen (BUN) (fig. S5B). Tissue in-
flammation and immune response were also studied. Hematoxylin and 
eosin (H&E) staining results indicated slight neutrophil infiltration 
on day 3 after administration of F-insulin–loaded PF-127 gel, which 
was resolved by day 7 (fig. S5C). Masson’s trichrome staining results 
also indicated neutrophil infiltration for PF-127 gel with or without 
loading F-insulin (fig. S6). However, neutrophil infiltration was 
limited in F-insulin–treated mice. Furthermore, negligible fibrosis was 
formed for all treated groups during and after treatment (fig. S6). 
Consistently, slight macrophage infiltration was observed at the ad-
ministration site of mice treated with either blank or F-insulin–loaded 
PF-127 gel on day 3 after treatment (fig. S7).
F-insulin could also be easily loaded into a dissolvable microneedle 
(MN) array patch made from polyvinylpyrrolidone (PVP) (Fig. 4G). 
The insulin release from the complex loaded in the MN patch was 
promoted in the presence of glucose, which is vital for in vivo applica-
tion of complex-loaded patch (fig. S8A). The glucose levels of type 1 
diabetic mice treated with MN–F-insulin slowly decreased to ~100 mg/
dl and were maintained below 200 mg/dl for up to 6 hours, much 
longer than that of mice treated with MN-insulin (Fig. 4H). IPGTT was 
also carried out at 3 hours after treatment of MN–F-insulin (fig. S8B). 
Plasma insulin level increased from 20 to 160 U/ml, associated with a 
spike in BGLs (Fig. 4I), and then gradually decreased to 16 U/ml.
In vivo evaluation of the complex in diabetic pigs
The diabetes treatment efficacy of F-insulin was further evaluated in a 
STZ-induced diabetic Göttingen minipig model using a continuous 
glucose monitoring system (CGMS). Similar to the results obtained in 
diabetic mice, F-insulin showed significantly prolonged BGL- 
regulating effect in pigs as compared with native insulin (Fig. 5A). The 
BGLs of each pig treated with F-insulin displayed a relatively “flat” 
stage around 100 mg/dl during the treatment, likely due to the en-
hanced insulin release from F-insulin when the BGLs gradually 
increased from 40 mg/ml to 100 mg/dl. As shown, the BGLs may fall 
below 40 mg/dl that could not be read in detail by CGMS due to its 
detection limit. In normal pigs, glucose levels below 40 mg/dl are 
common and well described using CGMS (51). Furthermore, pigs 
were carefully watched during the treatment, with sampled blood 
monitored with a blood glucose meter (table S1). No symptoms of 
hypoglycemia were identified. In addition, oral glucose tolerance tests 
were carried out at an insulin dose of 0.5 U/kg. The subsequent glucose 
challenge led to an immediate increase of BGLs to the upper detection 
limit of CGMS if the pigs were treated with insulin (Fig. 5B). In con-
trast, the insulin complex treatment obviously inhibited the increase of 
BGLs. Furthermore, intravenously infused dextrose solution led to a 
sharp increase of BGLs, which effectively induced spikes of accompa-
nying serum insulin for F-insulin–treated diabetic pigs (Fig. 5C), while 
no C-peptide (pig) spikes were observed (fig. S9A). In contrast, only a 
steady decrease of insulin level was observed due to clearance when the 
diabetic minipigs were treated with native insulin (fig. S9, B to D), sub-
stantiating that the serum insulin spikes of complex-treated minipigs 
were achieved because of the glucose- triggered insulin release.
DISCUSSION
To achieve glucose-responsive insulin release in vivo in a fast manner, 
we conceived the concept of engineering a positively charged polymer 
integrated with a glucose-sensing moiety, which could switch the 
positive charge of polymer to negative in response to increased glucose 
concentration. At neutral physiological pH, the prepared positively 
charged polymer can form a micro-sized stable water-insoluble com-
plex with insulin that could be injected subcutaneously. After adjusting 
the polymer structure and the ratio between polymer and insulin, 
an optimized complex (F-insulin) was obtained, showing robust 
glucose-dependent insulin release profile. In a type 1 diabetic mouse 
model, the complex showed prolonged blood glucose–regulating 
ability as compared to native insulin, while negligible hypoglycemia 
was observed at the dose studied. In addition, no obvious IgE, IgM, 
and IgG in response to F-insulin were generated during the whole 
treatment. Further long-term toxicity evaluation should be performed 
for potential translation.
This glucose-responsive formulation could be useful for controlling 
postprandial glucose levels, as it could increase the time window to 
start and complete a meal after administration. An acute glucose 
injection triggered a quick elevation of plasma insulin level associated 
with the blood glucose spike. The insulin level also decreased back to 
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basal levels after the BGL normalized, which could minimize the potential 
for hypoglycemia. While the results in diabetic mice were encouraging, 
prolonged glucose regulation was also demonstrated in the diabetic 
minipigs, verifying the sustained release of insulin from the complex. 
Intravenously infused dextrose raised the BGLs of F-insulin–treated 
diabetic minipigs, triggering insulin release. For future translation, 
as demonstrated, this complex formulation can be integrated with an 
injectable gel matrix for sustained long-term insulin release or a trans-
dermal MN array patch for painless and disposable administration.
MATERIALS AND METHODS
Materials
Ethylenediamine, di-tert-butyl decarbonate (Boc2O), acryloyl chloride, 
2,2′-azobis(2-methylpropionitrile) (AIBN), tetrahydrofuran (THF), 
trifluoroacetic acid (TFA), dichloromethane (CH2Cl2), NHS, and 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC•HCl) were purchased from Sigma-Aldrich. 4-Carboxy-3- 
florobenzeneboronic acid and 4-carboxybenzeneboronic acid were 
obtained from Fisher Scientific. Insulin used in this study was 
recombinant human insulin purchased from Thermo Fisher Scientific 
(catalog no. A11382IJ). Both weight unit “mg” and international 
unit “U” were used for insulin. Unless mentioned otherwise, all the 
reactions were carried out with the protection of N2 atmosphere.
Methods
Synthesis of Boc-EDA
Ethylenediamine (14 ml) was dissolved in CHCl3 (200 ml) and 
cooled in an ice bath. Boc2O (4.1 g) dissolved in CHCl3 (50 ml) was 
added dropwise for 3 hours, and the reaction was stirred overnight 
at room temperature. After filtration, the solution was washed with 
saturated NaCl aqueous solution (3 × 50 ml), dried over anhydrous 
MgSO4, filtrated, and evaporated to obtain a colorless oil. This liq-
uid was used without further purification.
Synthesis of Boc-EDAA
Boc-EDA (1.6 g, 10 mmol) was dissolved in H2O (50 ml) and filtrated 
to obtain a clear solution, to which acryloyl chloride (1.5 g, 16 mmol) 
in THF (20 ml) was added. NaHCO3 (1.5 g) was then added slowly 
to the solution, and the reaction was stopped after an additional 30 min. 
The mixture was extracted using CH2Cl2 (3 × 50 ml), dried over 
anhydrous MgSO4, and filtrated. After evaporation of the solvent, 
white Boc-EDAA (1.6 g, yield 70%) was obtained. 1H NMR (400 MHz, 
in CDCl3, ): 6.54 (s, 1H), 6.22 (d, 1H), 6.1 (q, 1H), 5.6 (d, 1H), 5.02 
(s, 1H), 3.4 (q, 2H), 3.3 (s, 2H), and 1.42 (s, 9H).
Synthesis of poly(Boc-EDAA)
Boc-EDAA (0.5 g) and AIBN (12 mg) were mixed and dissolved in 
THF (2 ml), which was purged with N2 for 10 min. After incubation 
at 60°C overnight, the reaction mixture was diluted with THF (10 ml), 
added to water, and dialyzed against water (3 × 4 L). Last, the water 
was lyophilized, and a white solid was obtained (0.45 g, yield 90%).
Synthesis of poly(EDAA)
Poly(Boc-EDAA) (0.3 g) was added to CH2Cl2 (10 ml) containing 
TFA (3 ml) and stirred for 2 hours. After removing the solvent, the 
residual was dialyzed against water (3 × 4 liters) and lyophilized to 
obtain poly(EDAA) (0.2 g, yield 90%) as a slightly yellow solid.
Synthesis of PBA-NHS
4-Carboxyphenylboronic acid (2 g, 12 mmol) and NHS (2 g, 17 mmol) 
were mixed in dimethylformamide (DMF) (100 ml) and cooled in an 
Fig. 5. In vivo evaluation of F-insulin for treatment of type 1 diabetic minipig. (A) BGLs of type 1 diabetic minipigs treated with native insulin or F-insulin. The insulin 
dose was set to 1 U/kg. The BGLs were measured continuously by CGMS. Each curve represents the BGL change obtained from a single minipig. The same color indicated 
the data from the same pig. Three pigs (designated as 1, 2, or 3) were used in this study. The black arrow indicated the injection of insulin or F-insulin. The orange arrows 
indicated the two meals for pigs. (B) Oral glucose tolerance test toward diabetic minipigs at 4 hours after treatment of F-insulin (0.5 U/kg). Glucose was given at 0.5 g/kg. 
(C) Intravenous glucose tolerance test in diabetic minipigs at 4 hours after treatment of F-insulin at a dose of 1 U/kg. Dextrose solution (5%) was intravenously infused at 
a dose of 0.75 g/kg. The rate of infusion was set to 1 liter/hour. Figures from left to right indicated pigs 1, 2, and 3, respectively.
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ice bath while stirring. EDC•HCl (3 g, 18 mmol) was added, and the 
reaction was stirred overnight at room temperature. The mixture was 
poured into CH2Cl2 (200 ml), washed with HCl (0.1 N, 3 × 50 ml) 
and NaHCO3 (0.1 N, 3 × 50 ml) successively, and dried over anhy-
drous MgSO4. The solvent was evaporated under reduced pressure, 
and a pure white PBA-NHS was obtained (3 g, yield 90%). 1H NMR 
[400 MHz, in dimethyl sulfoxide (DMSO)–d6, ]: 8.43 (s, 2H), 8.02 (t, 
4H), and 2.88 (s, 4H).
Synthesis of FPBA-NHS
FPBA (2 g, 12 mmol) and NHS (2 g, 17 mmol) were mixed in DMF 
(100 ml) and cooled in an ice bath while stirring. EDC•HCl (3 g, 18 mmol) 
was added, and the reaction was stirred overnight at room temperature. 
The mixture was poured into CH2Cl2 (200 ml), washed with HCl 
(0.1 N, 3 × 50 ml) and NaHCO3 (0.1 N, 3 × 50 ml) successively, and 
dried over anhydrous MgSO4. The solvent was evaporated under re-
duced pressure, and a pure white FPBA-NHS was obtained (2.7 g, 
yield 80%). 1H NMR (400 MHz, in DMSO-d6, ): 8.59 (s, 2H), 8.0 
(t, 1H), 7.79 (q, 2H), and 2.9 (s, 4H).
Synthesis of FPBA-modified poly(EDAA), with poly(EDAA0.4-FPBA0.6) 
as an example
Poly(EDAA) (0.15 g) was dissolved in deionized water (10 ml). FPBA- 
NHS (220 mg) dissolved in DMSO (2 ml) was added to give a clear 
solution. Then, solid NaHCO3 was added slowly to maintain the pH 
around 7.2, and the reaction was stirred for 30 min. Last, the mix-
ture was dialyzed against deionized water (3 × 4 liters) and subse-
quently lyophilized to give a white solid (0.3 g, yield 80%).
Synthesis of RhB-insulin
Rhodamine B isothiocyanate (1 mg) dissolved in DMSO (1 ml) was 
added to the aqueous solution of insulin (100 mg). Solid NaHCO3 
was added carefully to adjust the solution to pH 8, and the reaction 
was further stirred overnight. Then, the mixture was dialyzed against 
deionized H2O (3 × 4 liters) and lyophilized to obtain RhB-insulin.
Preparation of polymer nanoparticles
Poly(EDAA0.4-FPBA0.6) (1 mg) was dissolved in acidified deionized 
H2O (50 l). Upon rapid addition of PBS (10 mM, pH 7.4, 1 ml) to 
this solution, the polymer precipitated and formed stable nano-
particles. Nanoparticle solution from poly(EDAA0.4-PBA0.6) was 
prepared by the same method.
Preparation of insulin complex
We described the preparation of poly(EDAA0.4-FPBA0.6)–insulin 
complex as an example. Both insulin (1 mg, 28.8 U) and poly(EDAA0.4- 
FPBA0.6) (1 mg) were dissolved in acidified H2O (50 l) and mixed. 
NaOH aqueous solution (0.1 N) was added carefully, and the pH 
was finely tuned to 7.4 until a white precipitate formed. To this sus-
pension, PBS (10 mM, pH 7.4, 1 ml) was added, and the mixture 
was centrifuged. The precipitate was further washed for several times 
with PBS. Last, the suspension was kept in PBS 7.4 and used directly 
for further experiment. The insulin loading capacity (LC) is defined 
as LC = A/B, and the loading efficiency (LE) is defined as LE = A/C, 
where A is the amount of insulin loaded in complex, B is the total 
weight of complex, and C is the insulin amount used.
Size and  potential of nanoparticles
The size and  potential of nanoparticles were measured on a Zetasizer 
instrument (Malvern). The impact of glucose concentration on the 
 potential of nanoparticles was determined by adding various amounts 
of glucose (0.3 g/ml) to the solution of nanoparticles, which stood for 
2 min before taking the measurement. Nanoparticles of poly(EDAA0.4- 
FPBA0.6) would precipitate when glucose was added to 400 mg/dl, 
and rapid ascertainment of this measurement was critical.
Observation of polymer nanoparticles by TEM
Nanoparticle aqueous solution (0.5 mg/ml, 10 l) was dropped onto 
a copper grip and stayed for 30 min before a filtrate paper was used to 
remove the residual solution. Then, uranyl acetate solution (5%, 10 l) 
was added onto the copper grip and stayed for 10 min, and a filtrate 
paper was also used to remove the solution. After further drying for 
1 hour, the sample was observed on a JEOL 2000FX TEM.
The glucose adsorption study
Insulin complexes, composed of insulin (1 mg, 28.8 U) and polymer (1 mg), 
were suspended in PBS 7.4 (1 ml), to which glucose (0.3 g/ml) was added 
to acquire various glucose concentrations (100, 200, or 400 mg/dl). 
This mixture was incubated at 37°C, and the glucose concentration in 
the supernatant was monitored with a Clarity GL2Plus glucose meter. 
The concentration was calculated according to a standard curve.
In vitro insulin release study
Briefly, insulin (1 mg, 28.8 U) loaded in complexes of different poly-
mers was allocated to centrifuge tubes containing PBS (pH 7.4, 1 ml), 
and various amounts of glucose (0.3 g/ml) were added to prepare 
different concentrations (0, 100, 200, and 400 mg/dl). Then, the 
centrifuge tubes were incubated at 37°C and vibrated. At timed 
intervals, a clear supernatant solution (10 l) collected through cen-
trifuge was further added to Coomassie blue (200 l). The absorbance 
of the solution was measured at 595 nm, and the concentration was 
calibrated using an established standard curve. In other cases, RhB- 
insulin was used, and the fluorescence intensity was recorded at 580 nm 
(excited at 540 nm).
Animal study
The animal (both mice and minipig) study was approved by the 
Institutional Animal Care and Use Committee at North Carolina 
State University and the University of North Carolina at Chapel Hill. 
The C57BL/6J mice were maintained in a specific pathogen–free 
room with a 12:12 light-dark cycle. The diabetic mouse model was 
induced using STZ. Typically, after overnight fasting, male C57BL/6J 
mice (6 to 8 weeks old) were intraperitoneally injected with STZ 
(150 mg/kg). After 1 week, the mice with fasting blood glucose 
higher than 300 mg/dl were confirmed as type 1 diabetic mice, which 
were used for further experiment. During the treatment experiment, 
the diabetic mice were normally fed with food, and the experiments 
were started in the morning.
Blood glucose control study in type 1 diabetic mice
Diabetic mice were allocated to different groups and treated with 
subcutaneously injected native insulin or complexes at an insulin- 
equivalent dose of 80 U/kg or complex-loaded in PF-127 gel at an 
insulin-equivalent dose of 300 U/kg. The BGLs were monitored with 
a Clarity GL2Plus glucose meter. PF-127 was prepared as 50% in 
aqueous solution, and the complex was suspended in the gel. Before 
injection, the gel was kept at 4°C for improving fluidity to facilitate 
subcutaneous injection. For the 2-week-long treatment, the diabetic 
mice were treated at a dose of 80 U/kg, with two injections (9 a.m. 
and 6 p.m.) each day.
Plasma insulin level measurement
The plasma insulin level was measured by collecting 20 l of plasma, 
which was stored at −20°C until measurement using a human insulin 
enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen, USA).
Biodistribution study
Fluorescence imaging of the diabetic mice treated with either sub-
cutaneously injected native insulin labeled with sulfo-Cy5 or 
F-insulin composed of sulfo-Cy5–labeled insulin was measured with 
the IVIS Spectrum Imaging System (PerkinElmer). The mice were
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anesthetized using isoflurane. Poly(EDAA0.4-FPBA0.6) was also 
labeled with Cy5 and mixed with unlabeled insulin for subcutaneous 
injection (80 U/kg). At the predetermined time points (1, 3, 8, 24, 
48, and 96 hours) after treatment, the mice were euthanized, and 
the primary organs were collected for imaging with the IVIS Spectrum 
Imaging System.
Intraperitoneal glucose tolerance test
Diabetic mice were allocated to different groups and treated with 
subcutaneously injected native insulin or complexes at a dose of 
80 U/kg. Then, glucose (0.4 g/ml) was given at 3 hours after treat-
ment at a dose of 1.5 g/kg, and BGLs were monitored with a Clarity 
GL2Plus glucose meter. For IPGTT-triggered insulin release from 
subcutaneous insulin depot, glucose (2 g/kg) was given at 4 hours 
after treatment of subcutaneously injected insulin glargine (80 U/kg) 
or F-insulin (80 U/kg) to achieve a clear spike of blood glucose. 
Blood (50 l) was collected at predetermined intervals, centrifuged 
to isolate plasma, and stored at −20°C until measurement.
Preparation of complex-loaded MN patch
Poly(EDAA0.4-FPBA0.6) (10 mg) and insulin (10 mg) were mixed to 
prepare F-insulin suspension, which was further allocated to five MN 
patch molds (20 × 20; base: 300 m, circle; body: 900 m, with 600-m 
cylindrical body and 300-m conical tip), and dried under vacuum. 
Then, PVP [10 weight % (wt %), 100 l] was placed on the MN molds 
and incubated under vacuum again to let the solution get into the 
MN holes, followed by the addition of another 500 l of PVP (10 wt %) 
solution. Then, the MN patch molds were placed under vacuum 
until dry. The MN array patch was observed on a scanning electron 
microscope (FEI Verios 460L).
In vivo study using MN array patch
Diabetic mice were allocated to different groups and treated with 
MN array patch loaded with complex or native insulin at an insulin- 
equivalent dose of 2 mg per mouse. The BGLs were monitored with 
a Clarity GL2Plus glucose meter. The plasma insulin levels were 
measured by collecting 50 l of blood, and the plasma was isolated 
and stored at −20°C until measurement. For IPGTT-triggered insulin 
release, glucose (0.4 g/ml, 2 g/kg) was given at 3 hours after treatment 
of F-insulin loaded in MN array patch.
Glucose control studies of complexes using STZ-induced 
diabetic minipigs
All pig studies were carefully monitored by veterinarians to deal 
with potential hypoglycemia. Göttingen minipigs (6 months old) 
were injected with STZ (150 mg/kg) to establish the diabetic minipig 
model. Three diabetic pigs (35, 32, and 28 kg for pigs 1, 2, and 3, 
respectively) were treated with subcutaneously injected native insulin 
or complex at a dose of 1 U/kg after overnight fasting, and then 
two meals are provided normally during the treatment. The BGLs 
were continuously monitored using a CGMS (Dexcom G4).
Oral glucose tolerance tests in diabetic pigs
Three diabetic pigs were treated with subcutaneously injected native 
insulin or complex at a dose of 0.5 U/kg after overnight fasting, and 
then glucose (0.5 g/kg) was given at 4 hours after treatment. The 
BGLs were continuously monitored using a CGMS.
Intravenous glucose administration triggered insulin release
Three diabetic pigs were treated with subcutaneously injected native 
insulin or complex at a dose of 1 U/kg after overnight fasting. Four hours 
later, dextrose (5 wt %) solution was infused at a dose of 0.75 g/kg 
at a rate of 1  liter/hour, while the pigs were kept anesthetized 
using isoflurane. Blood was collected from external jugular vein 
before and during the experiment at predetermined intervals to 
measure BGLs. In addition, serum was also collected from the blood 
samples using a serum separator tube (BD) for subsequent insulin 
level measurement using Iso-Insulin ELISA (Mercodia).
H&E staining experiment
The inflammation caused by subcutaneous injection of the complex- 
loaded PF-127 gel was evaluated. After the removal of the back hair, 
diabetic mice were subcutaneously injected with PF-127 (100 l) 
loaded with insulin complex (300 U/kg). On day 3 or 7 after injection, 
mice were euthanized, and pieces of skin from the treated or un-
treated sites were collected and fixed in 4% formaldehyde and 
proceeded for H&E staining. The images were taken using a micro-
scope (Olympus).
Masson’s trichrome staining and macrophage staining
Diabetic mice were subcutaneously injected with F-insulin (80 U/kg), 
PF-127 (blank), or PF-127 gel loaded with F-insulin (300 U/kg). At 
the predetermined time point, the diabetic mice were euthanized, 
and the skin from the treated sites was collected. Part of each piece 
of the skin was fixed in 4% formaldehyde and proceeded for Masson’s 
trichrome staining. The images were taken using a microscope 
(LAXCO, LMI6-PH2). The skin left was subject to cryosection (10 m) 
and proceeded for macrophage staining. The macrophage was 
stained with rat monoclonal antibody to F4/80 purchased from 
Abcam (lot no. GR3250648-1) and Alexa Fluor 488–labeled goat 
polyclonal antibody to rat IgG purchased from Abcam (lot no. 
GR3234544-1). The macrophage was shown in green. The nuclei were 
stained with 4′,6-diamidino-2-phenylindole (DAPI) and shown in 
blue. The fluorescence image was observed on a confocal microscope 
(Zeiss LSM710).
Host response and toxicity evaluation
Diabetic mice were continuously treated with F-insulin (80 U/kg), 
native insulin (80 U/kg), insulin glargine (80 U/kg), or PBS for 
2 weeks. Each mouse received two injections per day (9 a.m. and 
6 p.m.). The serum was collected for evaluating the immunoglobin 
levels using ELISA purchased from Abcam (catalog nos. ab157719, 
ab215085, and ab157718). Whole blood was also obtained for complete 
blood count, while AST, ALB, and BUN in serum were detected for 
evaluating toxicity toward the liver and kidney.
Statistical analysis
All data were shown as the means ± SD. One-way analysis of variance 
(ANOVA) with Tukey post hoc tests was used to carry out multiple 
comparisons, while Student’s t test was used to analyze the difference 
between two groups.
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